These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29725696)

  • 1. [Autoimmune hepatitis-standard and second-line therapy].
    Taubert R; Jaeckel E
    Internist (Berl); 2018 Jun; 59(6):536-543. PubMed ID: 29725696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic strategies for autoimmune hepatitis.
    Manns MP; Strassburg CP
    Dig Dis; 2011; 29(4):411-5. PubMed ID: 21894012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
    Stoelinga AEC; Tushuizen ME; van den Hout WB; Girondo MDMR; de Vries ES; Levens AD; Moes DAR; Gevers TJG; van der Meer S; Brouwer HT; de Jonge HJM; de Boer YS; Beuers UHW; van der Meer AJ; van den Berg AP; Guichelaar MMJ; Drenth JPH; van Hoek B;
    Trials; 2024 Jan; 25(1):61. PubMed ID: 38233878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Pronk MAMCB; Beuers UHW; van der Meer AJ; van Gerven NMF; Sijtsma MGM; Verwer BJ; Gisbertz IAM; Bartelink M; van den Brand FF; Sebib Korkmaz K; van den Berg AP; Guichelaar MMJ; Soufidi K; Levens AD; van Hoek B; Drenth JPH;
    Trials; 2022 Dec; 23(1):1012. PubMed ID: 36514163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Autoimmune liver diseases and their overlap syndromes].
    Strassburg CP
    Praxis (Bern 1994); 2006 Sep; 95(36):1363-81. PubMed ID: 16989180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge issues in autoimmune hepatitis.
    Liberal R; Krawitt EL; Vierling JM; Manns MP; Mieli-Vergani G; Vergani D
    J Autoimmun; 2016 Dec; 75():6-19. PubMed ID: 27502148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and therapy of autoimmune hepatitis.
    Granito A; Muratori P; Ferri S; Pappas G; Quarneti C; Lenzi M; Bianchi FB; Muratori L
    Mini Rev Med Chem; 2009 Jun; 9(7):847-60. PubMed ID: 19519509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
    Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
    Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune hepatitis.
    Mieli-Vergani G; Heller S; Jara P; Vergani D; Chang MH; Fujisawa T; González-Peralta RP; Kelly D; Mohan N; Shah U; Murray KF
    J Pediatr Gastroenterol Nutr; 2009 Aug; 49(2):158-64. PubMed ID: 19561543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options to treat autoimmune hepatitis in 2009.
    Strassburg CP
    Dig Dis; 2010; 28(1):93-8. PubMed ID: 20460896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of autoimmune hepatitis.
    Strassburg CP; Manns MP
    Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):673-87. PubMed ID: 22117634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert clinical management of autoimmune hepatitis in the real world.
    Liberal R; de Boer YS; Andrade RJ; Bouma G; Dalekos GN; Floreani A; Gleeson D; Hirschfield GM; Invernizzi P; Lenzi M; Lohse AW; Macedo G; Milkiewicz P; Terziroli B; van Hoek B; Vierling JM; Heneghan MA;
    Aliment Pharmacol Ther; 2017 Mar; 45(5):723-732. PubMed ID: 28004405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune hepatitis.
    Thiele DL
    Clin Liver Dis; 2005 Nov; 9(4):635-46, vi. PubMed ID: 16207568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of autoimmune hepatitis-First-line, second-line and third-line treatment].
    Taubert R; Engel B
    Inn Med (Heidelb); 2024 Apr; 65(4):325-333. PubMed ID: 38456902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIH: Which Alternative for Difficult-to-Treat Patients?
    Sebode M; Schramm C
    Dig Dis; 2015; 33 Suppl 2():83-7. PubMed ID: 26641096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of autoimmune hepatitis: a review of current and evolving therapies.
    Jothimani D; Cramp ME; Mitchell JD; Cross TJ
    J Gastroenterol Hepatol; 2011 Apr; 26(4):619-27. PubMed ID: 21073674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management of autoimmune hepatitis.
    Pape S; Schramm C; Gevers TJ
    United European Gastroenterol J; 2019 Nov; 7(9):1156-1163. PubMed ID: 31700628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune hepatitis: Unveiling faces.
    Zhu JY; Han Y
    J Dig Dis; 2015 Sep; 16(9):483-8. PubMed ID: 26332151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune hepatitis in children: what is different from adult AIH?
    Mieli-Vergani G; Vergani D
    Semin Liver Dis; 2009 Aug; 29(3):297-306. PubMed ID: 19676002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.